Use of mycophenolate mofetil in kidney transplant recipients with viral hepatitis infection: is it justified?

Transplant Proc. 2002 Dec;34(8):3217-9. doi: 10.1016/s0041-1345(02)03697-7.

Authors

V Sumethkul¹, A Ingsathit, P Leelasa-Nguan, S Jirasiritham

Affiliation

¹ Department of Medicine, Ramathibodi Hospital, Bangkok, Thailand. ravsm@mahidol.ac.th

PMID: 12493425
DOI: 10.1016/s0041-1345(02)03697-7

No abstract available

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Follow-Up Studies
Graft Survival
Hepatitis B / complications
Hepatitis B / immunology*
Hepatitis B Surface Antigens / blood
Hepatitis C / complications
Hepatitis C / immunology*
Hepatitis C Antibodies / blood
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Kidney Transplantation / immunology*
Kidney Transplantation / mortality
Kidney Transplantation / physiology
Mycophenolic Acid / adverse effects
Mycophenolic Acid / analogs & derivatives
Mycophenolic Acid / therapeutic use*
Survival Analysis
Time Factors

Substances

Hepatitis B Surface Antigens
Hepatitis C Antibodies
Immunosuppressive Agents
Mycophenolic Acid